Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.
Saved in:
| Title: | Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. |
|---|---|
| Authors: | Hudeček J; 1Department of Research IT, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Voorwerk L; 2Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Seijen M; 3Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Nederlof I; 2Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Maaker M; 3Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Berg J; 4Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Vijver KK; 5Department of Pathology, Ghent University Hospital, Ghent, Belgium., Sikorska K; 6Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Adams S; 7Department of Medicine, Perlmutter Cancer Center, New York University School of Medicine, New York, NY USA., Demaria S; 8Department of Radiation Oncology, Weill Cornell Medicine, New York, NY USA.; 9Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY USA., Viale G; 10International Breast Cancer Study Group Central Pathology Office, Department of Pathology and Laboratory Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy.; 11University of Milan, Milan, Italy., Nielsen TO; 12Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC Canada., Badve SS; 13Department of Pathology and Laboratory Medicine, Indiana University Simon Cancer Center, Indianapolis, IN USA., Michiels S; 14Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Université-Paris Sud, Université Paris-Saclay, Villejuif, France.; 15CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France., Symmans WF; 16Department of Pathology, M.D. Anderson Cancer Center, Houston, TX USA., Sotiriou C; 17Breast Cancer Translational Research Laboratory, Institut Jules Bordet, U-CRC, Université Libre de Bruxelles, Brussels, Belgium., Rimm DL; 18Department of Pathology, Yale School of Medicine, New Haven, CT USA.; 19Department of Medicine, Yale University School of Medicine, New Haven, CT USA., Hewitt SM; 20Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD USA., Denkert C; 21Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.; 22Institute of Pathology, Philipps-University Marburg, Marburg, Germany., Loibl S; 23German Breast Group, Neu-Isenburg, Germany., Loi S; 24Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC Australia., Bartlett JMS; 25Ontario Institute for Cancer Research, Toronto, ON Canada.; 26IGMM, Edinburgh, UK.; 27Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK., Pruneri G; 28Department of Pathology and Laboratory Medicine, IRCCS Fondazion - Instituto Nazionale Tumori, Milan, Italy.; 29School of Medicine, University of Milan, Milan, Italy., Dillon DA; 30Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA USA., Cheang MCU; 31Clinical Trials and Statistics Unit, The Institute of Cancer Research, Surrey, UK., Tutt A; 32Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Hall JA; Research and Development, Vivactiv Ltd, Chesham, Buckinghamshire UK., Kos Z; 34Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, ON Canada., Salgado R; 24Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC Australia.; Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium., Kok M; 2Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; 36Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Horlings HM; 3Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; 4Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. |
| Corporate Authors: | International Immuno-Oncology Biomarker Working Group |
| Source: | NPJ breast cancer [NPJ Breast Cancer] 2020 May 12; Vol. 6, pp. 15. Date of Electronic Publication: 2020 May 12 (Print Publication: 2020). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: eCollection Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2374-4677 |
|---|---|
| DOI: | 10.1038/s41523-020-0155-1 |
